The FDA might take until fall to decide on Hemispherx BioPharma's application for Ampligen, an experimental treatment for chronic fatigue syndrome, because of staffing problems, said Dr. William Carter, the company's president and CEO. The biotech firm, which Carter said has been communicating with the FDA since May, is in discussions with potential marketing partners while the agency reviews the product.

Related Summaries